

# Global Non-alcoholic Steatohepatitis Treatment Market Size study, by Drug (Vitamin E & Pioglitazone, Resmetirom), Disease Stage, Distribution Channel, and Regional Forecasts 2022–2032

<https://marketpublishers.com/r/G05C06065118EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G05C06065118EN

## Abstracts

Global Non-alcoholic Steatohepatitis (NASH) Treatment Market is valued approximately at USD 6.03 billion in 2023 and is projected to grow at a remarkable CAGR of 28.10% over the forecast period 2024 to 2032. Non-alcoholic steatohepatitis, a severe and progressive form of non-alcoholic fatty liver disease, is rapidly becoming a global health concern, fueled by the explosion of sedentary lifestyles, obesity, and metabolic syndrome. Characterized by liver inflammation and damage caused by a buildup of fat in the liver, NASH often progresses silently until advanced stages such as fibrosis or cirrhosis emerge. The market for its treatment, long underpenetrated, is now experiencing an aggressive wave of therapeutic innovation, ushered in by drug candidates like Resmetirom and advanced Vitamin E-Pioglitazone regimens, both of which are being positioned as linchpins in emerging treatment protocols.

Breakthroughs in hepatic disease research and accelerated clinical trials have significantly transformed the competitive landscape, allowing biopharmaceutical firms to chase a once-underserved segment with fervor. The convergence of molecular diagnostics, predictive biomarkers, and precision medicine approaches has made it possible to identify patients at early and intermediate stages, enabling proactive disease intervention. Moreover, public-private funding initiatives and collaborative frameworks with academic institutions are catalyzing the commercial pipeline of investigational NASH drugs. The escalating number of FDA fast-track designations also reflects the urgency and opportunity embedded in this therapeutic area. Yet, challenges such as drug safety, regulatory hurdles, and heterogeneity in patient response present formidable barriers that companies must strategically navigate.

Rising awareness campaigns, expanding diagnostic capabilities, and integration of digital pathology platforms have allowed healthcare systems to better screen and stratify patient populations. Furthermore, as pharmacoeconomic evaluations gain traction among payers, the spotlight is now on demonstrating real-world effectiveness, not just trial efficacy. This demand for value-based care is shaping how future therapies will be priced, accessed, and reimbursed. Meanwhile, drug developers are also investing in combination therapies and exploring anti-inflammatory, anti-fibrotic, and metabolic pathways simultaneously to produce holistic treatment paradigms.

North America currently leads the global NASH treatment market, driven by high obesity prevalence, robust R&D infrastructure, and favorable regulatory conditions. Europe follows closely, with nations like Germany and France investing heavily in hepatic disease monitoring and patient outreach programs. Asia Pacific is anticipated to witness the fastest growth due to an alarming uptick in lifestyle disorders, surging awareness, and improving access to specialized care in populous nations like India, China, and Japan. Additionally, Latin America and the Middle East & Africa are opening up new frontiers, supported by growing healthcare infrastructure, local manufacturing incentives, and international NGO collaborations aimed at tackling chronic diseases.

Major market player included in this report are:

Gilead Sciences, Inc.

Madrigal Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Novartis AG

Bristol-Myers Squibb Company

Pfizer Inc.

Merck & Co., Inc.

Takeda Pharmaceutical Company Limited

Galmed Pharmaceuticals Ltd.

Genfit SA

89bio, Inc.

Viking Therapeutics, Inc.

Akero Therapeutics, Inc.

Terns Pharmaceuticals, Inc.

Sagimet Biosciences

The detailed segments and sub-segment of the market are explained below:

#### By Drug

Vitamin E & Pioglitazone

Resmetirom

#### By Disease Stage

Early Stage

Intermediate Stage

Advanced Fibrosis

#### By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

## By Region:

### North America

U.S.

Canada

### Europe

UK

Germany

France

Spain

Italy

Rest of Europe

### Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

## Latin America

Brazil

Mexico

Rest of Latin America

## Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

## Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market

## Contents

### **CHAPTER 1. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS TREATMENT MARKET EXECUTIVE SUMMARY**

- 1.1. Global NASH Treatment Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By Drug
  - 1.3.2. By Disease Stage & Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL NASH TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Payer & Patient Perspectives)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Patient Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **CHAPTER 3. GLOBAL NASH TREATMENT MARKET DYNAMICS**

### 3.1. Market Drivers

- 3.1.1. Escalating Prevalence of Obesity and Metabolic Syndrome
- 3.1.2. Surge in R&D and Fast-Track Regulatory Designations
- 3.1.3. Adoption of Precision Medicine and Biomarker-Guided Therapies

### 3.2. Market Challenges

- 3.2.1. Safety and Tolerability Concerns in Novel Agents
- 3.2.2. Complex Regulatory Pathways and Approval Delays
- 3.2.3. Heterogeneity in Patient Response and Disease Presentation

### 3.3. Market Opportunities

- 3.3.1. Expansion of Combination and Multi-Modal Treatment Regimens
- 3.3.2. Growth of Digital Diagnostics and Non-Invasive Fibrosis Assessment
- 3.3.3. Penetration into Emerging Markets with Rising Lifestyle Disease Burden

## **CHAPTER 4. GLOBAL NASH TREATMENT MARKET INDUSTRY ANALYSIS**

### 4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### 4.3. Top Investment Opportunities

### 4.4. Top Winning Strategies

### 4.5. Disruptive Trends

### 4.6. Industry Expert Perspective

### 4.7. Analyst Recommendation & Conclusion

## **CHAPTER 5. GLOBAL NASH TREATMENT MARKET SIZE & FORECASTS BY DRUG, 2022–2032**

- 5.1. Segment Dashboard
- 5.2. Vitamin E & Pioglitazone Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.3. Resmetirom Revenue Trend Analysis, 2022 & 2032 (USD Million)

## **CHAPTER 6. GLOBAL NASH TREATMENT MARKET SIZE & FORECASTS BY DISEASE STAGE & DISTRIBUTION CHANNEL, 2022–2032**

- 6.1. Segment Dashboard
- 6.2. Early Stage Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.3. Intermediate Stage Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.4. Advanced Fibrosis Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.5. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.6. Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.7. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Million)

## **CHAPTER 7. GLOBAL NASH TREATMENT MARKET SIZE & FORECASTS BY REGION, 2022–2032**

- 7.1. North America Market
  - 7.1.1. U.S. Market
    - 7.1.1.1. Drug & Stage Breakdown & Forecasts, 2022–2032
    - 7.1.1.2. Distribution Channel Breakdown & Forecasts, 2022–2032
  - 7.1.2. Canada Market
- 7.2. Europe Market
  - 7.2.1. UK Market
  - 7.2.2. Germany Market
  - 7.2.3. France Market
  - 7.2.4. Spain Market
  - 7.2.5. Italy Market
  - 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
  - 7.3.1. China Market
  - 7.3.2. India Market
  - 7.3.3. Japan Market
  - 7.3.4. Australia Market
  - 7.3.5. South Korea Market
  - 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
  - 7.4.1. Brazil Market

- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
  - 7.5.1. Saudi Arabia Market
  - 7.5.2. South Africa Market
  - 7.5.3. Rest of Middle East & Africa Market

## **CHAPTER 8. COMPETITIVE INTELLIGENCE**

- 8.1. Key Company SWOT Analysis
  - 8.1.1. Gilead Sciences, Inc.
  - 8.1.2. Madrigal Pharmaceuticals, Inc.
  - 8.1.3. Intercept Pharmaceuticals, Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
  - 8.3.1. Gilead Sciences, Inc.
    - 8.3.1.1. Key Information
    - 8.3.1.2. Overview
    - 8.3.1.3. Financial (Subject to Data Availability)
    - 8.3.1.4. Product Summary
    - 8.3.1.5. Market Strategies
  - 8.3.2. Madrigal Pharmaceuticals, Inc.
  - 8.3.3. Intercept Pharmaceuticals, Inc.
  - 8.3.4. Novartis AG
  - 8.3.5. Bristol-Myers Squibb Company
  - 8.3.6. Pfizer Inc.
  - 8.3.7. Merck & Co., Inc.
  - 8.3.8. Takeda Pharmaceutical Company Limited
  - 8.3.9. Galmed Pharmaceuticals Ltd.
  - 8.3.10. Genfit SA
  - 8.3.11. 89bio, Inc.
  - 8.3.12. Viking Therapeutics, Inc.
  - 8.3.13. Akero Therapeutics, Inc.
  - 8.3.14. Terns Pharmaceuticals, Inc.
  - 8.3.15. Sagimet Biosciences

## **CHAPTER 9. RESEARCH PROCESS**

- 9.1. Research Process

- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes

## I would like to order

Product name: Global Non-alcoholic Steatohepatitis Treatment Market Size study, by Drug (Vitamin E & Pioglitazone, Resmetirom), Disease Stage, Distribution Channel, and Regional Forecasts 2022–2032

Product link: <https://marketpublishers.com/r/G05C06065118EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G05C06065118EN.html>